Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Pfizer (PFE), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the q...

System1 Group (AIM:SYS1) PLC climbed 23% on Wednesday as the marketing firm said recent deals with the likes of Tesco, Pfizer and M&S meant full-year expectations would be smashed. Some 60 new clie...

Pfizer's (PFE) revenues are expected to have declined in the fourth quarter of 2023 due to a steep decline in sales of its COVID-19 products on lower demand.

Pfizer faces declining demand for its COVID-19 products and upcoming patent expirations for several top-selling products. However, the company's future appears brighter than its current situation m...

Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pfizer stock is popular among dividend growth investors due to its 14-year dividend growth streak and 6% yield. The company has strong underlying fundamentals, including an A credit rating from S&P...

Last November, I found Pfizer cheaply valued, but I failed to identify a catalyst that could drive PFE stock higher in the foreseeable future. Pfizer's priorities are changing today, with the CEO p...

In trading on Wednesday, shares of Pfizer (NYSE:PFE) were yielding above the 6% mark based on its quarterly dividend (annualized to $1.68), with the stock changing hands as low as $27.93 on the day...

In the closing of the recent trading day, Pfizer (PFE) stood at $28.32, denoting a -1.32% change from the preceding trading day.

Albert Bourla told Barron's Andy Serwer that he's "all in" on Pfizer stock. He wants investors to believe.

Pfizer enjoyed huge financial gains thanks to its breakthrough products to combat COVID-19. 2023 was a different story, however, as demand for its COVID vaccines stalled.

Though there are reasons to like Pfizer's long-term prospects, the near term may continue to be challenging. Pfizer's CEO recently expressed disappointment in the company's -- and the stock's -- 20...

Pfizer Inc. stock has been on a protracted, yearlong decline due to stronger-than-expected normalization in COVID product uptake rates in 2023. But management's conservative 2024 guidance for COVID...

Post-pandemic, the global bio-pharmaceutical sector, often overlooked, presents undervalued opportunities, notably in blue-chip stocks like Pfizer (NYSE: PFE ). Following a 42% correction in the pa...

Pfizer (PFE) closed the most recent trading day at $29.40, moving -0.61% from the previous trading session.